Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12<sup/>.
The impact of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant (ASCT) was evaluated in a retrospective subgroup analysis of NCIC CTG LY.12. Among 414 patients who relapsed following R-CHOP, 96 received salvage chemotherapy alone [R - cohort]; and 318 received rituximab with chemotherapy [R + cohort] following a protocol amendment. The R-cohort had a higher proportion of patients with PS ≥2 and relapse <1 year after R-CHOP. The response rate (45.6% vs. 25.0%, p = 0.0003), CR/CRu (15.7% vs. 4.2%, p = 0.003) and transplantation rate (51.9% vs. 31.3%, p = 0.0004) was higher in the R + cohort. Event-free (27% vs. 22%, p = 0.0954) and overall survival at four years (43% vs. 31%; p = 0.045) were greater in the R + cohort when the patients with best response SD/PD to R-CHOP were excluded. Addition of rituximab to salvage therapy before ASCT appears to improve the response rate, transplantation rate, and overall survival in patients with CD20+ lymphoma who responded to R-CHOP.
a Department of Oncology, Cancer Centre of Southeastern Ontario , Queen's University , Kingston , ON , Canada.
Tara
T
Baetz
b Canadian Cancer Trials Group , Cancer Research Institute, Queen's University , Kingston , ON , Canada.
Bingshu E
BE
Chen
c Queen Elizabeth II Heath Sciences Centre , Halifax , NS , Canada.
Stephen
S
Couban
d Department of Oncology , Juravinski Hospital and Cancer Centre , Hamilton , ON , Canada.
C
C
Tom Kouroukis
e Department of Hematology/Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre , University of Toronto , Toronto , ON , Canada.
Rena
R
Buckstein
f Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre , University of Toronto , Toronto , ON , Canada.
John
J
Kuruvilla
g London Health Sciences Centre , London , ON , Canada.
Kang
K
Howson-Jan
h Department of Medicine , University of Manitoba , Winnipeg , MB , Canada.
David
D
Szwajcer
i Cattedra Di Oncologia Medica , Università Di Modena E Reggio Emilia , Modena , Italy.
Massimo
M
Federico
d Department of Oncology , Juravinski Hospital and Cancer Centre , Hamilton , ON , Canada.
Ralph M
RM
Meyer
b Canadian Cancer Trials Group , Cancer Research Institute, Queen's University , Kingston , ON , Canada.
Marina S
MS
Djurfeldt
b Canadian Cancer Trials Group , Cancer Research Institute, Queen's University , Kingston , ON , Canada.
Annette E
AE
Hay
b Canadian Cancer Trials Group , Cancer Research Institute, Queen's University , Kingston , ON , Canada.
Lois
L
Shepherd
f Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre , University of Toronto , Toronto , ON , Canada.
Michael
M
Crump
D000293:Adolescent; D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived; D000074322:Antineoplastic Agents, Immunological / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D003131:Combined Modality Therapy; D003520:Cyclophosphamide; D004317:Doxorubicin; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006801:Humans; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000378:metabolism / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016879:Salvage Therapy; D016019:Survival Analysis; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014750:Vincristine; D055815:Young Adult
D058846:Antibodies, Monoclonal, Murine-Derived; D000074322:Antineoplastic Agents, Immunological; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
Autologous transplant; rituximab; salvage chemotherapy